An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
United Therapeutics Corporation (Nasdaq: UTHR) will announce its fourth quarter and full year 2022 financial results on February 22, 2023, before market opening. A public webcast will follow at 9:00 a.m. Eastern Time on the same day, accessible on the company's website. As a pioneering public benefit corporation, United Therapeutics focuses on developing novel pharmaceutical therapies and technologies to enhance organ transplant availability for patients. The company emphasizes its mission to address unmet medical needs through innovation and stakeholder benefit.
Positive
United Therapeutics is a public benefit corporation, emphasizing patient care and innovative therapies.
The upcoming financial report may present opportunities for positive developments or growth metrics.
Negative
None.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2022 financial results before the market opens on Wednesday, February 22, 2023.
United Therapeutics will host a public webcast Wednesday, February 22, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one week and can be accessed at the same location.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.
You can learn more about what it means to be a PBC here: unither.com/PBC.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of February 15, 2023 and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
